Announced in Shanghai on June 14, 2026, CARsgen Therapeutics Holdings Limited, listed under Stock Code 2171.HK, disclosed details about their innovative CAR T-cell therapies. They presented posters for two products: CT0596, an allogeneic CAR T-cell therapy targeting BCMA, and CT1190B, another allogeneic CAR T-cell product.